157 related articles for article (PubMed ID: 2941177)
1. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.
Kangas L; Nieminen AL; Blanco G; Grönroos M; Kallio S; Karjalainen A; Perilä M; Södervall M; Toivola R
Cancer Chemother Pharmacol; 1986; 17(2):109-13. PubMed ID: 2941177
[TBL] [Abstract][Full Text] [Related]
2. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects.
Kallio S; Kangas L; Blanco G; Johansson R; Karjalainen A; Perilä M; Pippo I; Sundquist H; Södervall M; Toivola R
Cancer Chemother Pharmacol; 1986; 17(2):103-8. PubMed ID: 2941176
[TBL] [Abstract][Full Text] [Related]
3. Review of the pharmacological properties of toremifene.
Kangas L
J Steroid Biochem; 1990 Jun; 36(3):191-5. PubMed ID: 2142231
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
di Salle E; Zaccheo T; Ornati G
J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
[TBL] [Abstract][Full Text] [Related]
5. Introduction to toremifene.
Kangas L
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S3-7. PubMed ID: 2149282
[TBL] [Abstract][Full Text] [Related]
6. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
7. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
[TBL] [Abstract][Full Text] [Related]
8. Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro.
Kangas L; Nieminen AL; Cantell K
Med Biol; 1985; 63(4):187-90. PubMed ID: 2419713
[TBL] [Abstract][Full Text] [Related]
9. The oestrogen antagonists, tamoxifen and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro.
Paavonen T; Andersson LC
Clin Exp Immunol; 1985 Aug; 61(2):467-74. PubMed ID: 2931228
[TBL] [Abstract][Full Text] [Related]
10. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication.
Ebbs SR; Roberts J; Baum M
J Steroid Biochem; 1990 Jun; 36(3):239. PubMed ID: 2142244
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies with toremifene as an antitumor agent.
Robinson SP; Parker CJ; Jordan VC
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S9-17. PubMed ID: 2149286
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
Robinson SP; Jordan VC
Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
15. Toremifene as an anticancer agent.
Jordan VC
Cancer Invest; 1990; 8(2):271. PubMed ID: 2144785
[No Abstract] [Full Text] [Related]
16. Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.
Robinson SP; Mauel DA; Jordan VC
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1817-21. PubMed ID: 2975594
[TBL] [Abstract][Full Text] [Related]
17. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo.
Kangas L; Grönroos M
J Steroid Biochem; 1990 Jun; 36(3):253-7. PubMed ID: 2142248
[TBL] [Abstract][Full Text] [Related]
19. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice.
Iino Y; Takai Y; Ando T; Ohwada S; Yokoe T; Sugamata N; Takei H; Horiguchi J; Iijima K; Morishita Y
Cancer Chemother Pharmacol; 1994; 34(5):372-6. PubMed ID: 8070003
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
